<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">284</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2009-5-3-</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="ru">ЧРЕСКОЖНО ИМПЛАНТИРУЕМЫЕ ИНФУЗИОННЫЕ СИСТЕМЫ: РАСШИРЕНИЕ ВОЗМОЖНОСТЕЙ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Тимофеев</surname><given-names>Д. А.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Генералов</surname><given-names>М. И.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Балахнин</surname><given-names>П. В.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Белов</surname><given-names>А. Д.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Школьник</surname><given-names>М. И.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Суворова</surname><given-names>Ю. В.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Карелин</surname><given-names>М. И.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Таразов</surname><given-names>П. Г.</given-names></name><address><country country="RU">Russian Federation</country></address><email>michail@aeshkol.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>ФГУ Российский научный центр радиологии и хирургических технологий Федерального агентства по высокотехнологичной медицинской помощи, Санкт-Петербург</institution></aff><pub-date date-type="pub" iso-8601-date="2009-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2009</year></pub-date><volume>5</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2014-08-04"><day>04</day><month>08</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-08-04"><day>04</day><month>08</month><year>2014</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/284">https://oncourology.abvpress.ru/oncur/article/view/284</self-uri><abstract xml:lang="ru"><p>Представлены результаты комбинированного лечения инвазивного рака мочевого пузыря с использованием методов интервенционной радиологии.</p></abstract><kwd-group xml:lang="ru"><kwd>чрескожно имплантируемые инфузионные системы</kwd><kwd>рак мочевого пузыря</kwd><kwd>комбинированное лечение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Мерабишвили В.М. Онкологическая служба в Санкт-Петербурге и районах города в 2004 году; экспресс-информация популяционного ракового регистра. СПб., 2005.</mixed-citation><mixed-citation xml:lang="ru">Мерабишвили В.М. Онкологическая служба в Санкт-Петербурге и районах города в 2004 году; экспресс-информация популяционного ракового регистра. СПб., 2005.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Варламов С.А. Оптимизация лечения больных инвазивным раком мочевого пузыря. Автореф. дис. … канд. мед. наук. Томск, 1999.</mixed-citation><mixed-citation xml:lang="ru">Варламов С.А. Оптимизация лечения больных инвазивным раком мочевого пузыря. Автореф. дис. … канд. мед. наук. Томск, 1999.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Джабаров А.Ф., Русаков И.Г., Теплов А.А. Регионарная химиотерапия инвазивного рака мочевого пузыря. Рос онкол журн 2001;(2):35—37.</mixed-citation><mixed-citation xml:lang="ru">Джабаров А.Ф., Русаков И.Г., Теплов А.А. Регионарная химиотерапия инвазивного рака мочевого пузыря. Рос онкол журн 2001;(2):35—37.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Ganaha F., Yamada T., Ujita M. et al. Intraarterial low-dose Cisplatin via an Indvelling port and concurrent radiotherapy for invasive bladder cancer. JVIR 2001;12(3):379—84.</mixed-citation><mixed-citation xml:lang="ru">Ganaha F., Yamada T., Ujita M. et al. Intraarterial low-dose Cisplatin via an Indvelling port and concurrent radiotherapy for invasive bladder cancer. JVIR 2001;12(3):379—84.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Galetti T.P., Pontes J.E., Montie J. et al. Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder. J Urol 1989;142(5):1211—4.</mixed-citation><mixed-citation xml:lang="ru">Galetti T.P., Pontes J.E., Montie J. et al. Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder. J Urol 1989;142(5):1211—4.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Logothetis C.J., Samuels M.L., Selig D.E. et al. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. Cancer Treat Rep 1985;69(1):33—8.</mixed-citation><mixed-citation xml:lang="ru">Logothetis C.J., Samuels M.L., Selig D.E. et al. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. Cancer Treat Rep 1985;69(1):33—8.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Ogawa H., Nishimura T., Hori N. et al. 10-year survival rate in 92 patients with invasive bladder carcinoma treated by bladder sparing methods. Nippon Dca Daigaku Zasshi 1997;64(5)446—54.</mixed-citation><mixed-citation xml:lang="ru">Ogawa H., Nishimura T., Hori N. et al. 10-year survival rate in 92 patients with invasive bladder carcinoma treated by bladder sparing methods. Nippon Dca Daigaku Zasshi 1997;64(5)446—54.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Yip-Schneider M.T., Sweeney C.J., Jung S.H. et al. Cell Cycle Effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001;298(3):976—98.</mixed-citation><mixed-citation xml:lang="ru">Yip-Schneider M.T., Sweeney C.J., Jung S.H. et al. Cell Cycle Effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001;298(3):976—98.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Takashima S., Nakamura K., Nakatsuka H. et al. Means of effective and practical intraarterial chemotherapy for locally invasive bladder cancer — with special reference to clinical analysis of bladder cancer patients treated by intermittent intra-arterial infusion using an implantable port system. Hinyokika Kiyo 1999;45(2):127—31.</mixed-citation><mixed-citation xml:lang="ru">Takashima S., Nakamura K., Nakatsuka H. et al. Means of effective and practical intraarterial chemotherapy for locally invasive bladder cancer — with special reference to clinical analysis of bladder cancer patients treated by intermittent intra-arterial infusion using an implantable port system. Hinyokika Kiyo 1999;45(2):127—31.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
